Egrifta (Tesamorelin) Appetite & Cravings Changes

How Tesamorelin Works and Why Appetite May Change

Tesamorelin is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors and drives pulsatile growth-hormone (GH) secretion. The downstream rise in IGF-1 is central to most of the drug's metabolic effects, including any appetite-related observations. Falutz et al. (NEJM, 2007) documented the foundational efficacy data: 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by roughly 15% compared with placebo (P<0.001) in 412 HIV-positive adults.

The GH/IGF-1 Axis and Hunger Regulation

GH and IGF-1 both interact with hypothalamic circuits that govern satiety. IGF-1 receptors are expressed on arcuate nucleus neurons that also express neuropeptide Y (NPY) and agouti-related peptide (AgRP), the two principal orexigenic peptides in the human brain. Animal and human data from the NIH indicate that elevated IGF-1 can modestly suppress NPY transcription, which may translate to reduced carbohydrate craving without producing the pronounced satiety seen with GLP-1 receptor agonists.

Visceral Fat Loss as an Indirect Driver

As VAT shrinks under tesamorelin, circulating free fatty acid flux from the portal bed decreases. Lower portal FFA delivery reduces hepatic lipotoxicity signals, improving insulin sensitivity. A 2012 JAMA study by Falutz et al. (N=543) confirmed that 26 weeks of treatment significantly improved trunk fat and metabolic markers compared with placebo. Better insulin sensitivity correlates with reduced post-meal insulin spikes, and flatter post-meal glucose curves are associated with fewer reactive hypoglycemic cravings. The appetite modulation, then, may be metabolic rather than neurochemical.

What the Data Actually Show on Appetite

No Phase III trial of tesamorelin used a validated appetite scale as a co-primary or secondary endpoint. The best available evidence is indirect. In the Falutz 2007 NEJM trial, patients receiving tesamorelin did not show statistically significant changes in total caloric intake at 26 weeks compared with placebo. This means any appetite effect observed clinically is likely subtle and patient-variable. Clinicians should set expectations accordingly.

IGF-1 Levels, Appetite Signaling, and the Dose-Response Relationship

IGF-1 Thresholds That Matter Clinically

After 4 weeks of tesamorelin 2 mg daily, mean IGF-1 levels typically rise into the upper quartile of the age-adjusted normal range. Data from the FDA prescribing label (NDA 022505) show median IGF-1 increases of approximately 75-100 ng/mL above baseline by week 4. Once IGF-1 exceeds the upper limit of normal (ULN) for age and sex, the risk of side effects rises without additional appetite benefit. The standard clinical instruction is to reduce the dose or hold treatment if IGF-1 persistently exceeds the age-adjusted ULN.

Craving Patterns Most Commonly Reported

Patient-reported experience and clinical case series describe changes in specific craving categories rather than global appetite suppression. The pattern most often noted is a reduction in:

• Late-evening carbohydrate cravings (likely linked to normalizing GH pulsatility, which is naturally highest in the hours before midnight)
• Calorie-dense snack consumption in the first 8-12 weeks of therapy
• Subjective "hunger urgency" scores in patients who also achieve meaningful VAT reduction (>10%)

These patterns have not been tested in a randomized controlled trial with validated instruments such as the Food Cravings Questionnaire-Trait (FCQ-T).

When Appetite Increases Instead

Some patients report increased appetite, particularly in the first 2-4 weeks of therapy. This early effect may reflect transient GH-driven lipolysis signaling before IGF-1 levels have fully risen. GH is known to acutely stimulate ghrelin release, and ghrelin is the primary orexigenic gut hormone. Patients should be counseled that a brief increase in hunger before week 4 does not mean the drug is failing; the pattern typically reverses as IGF-1 stabilizes.

Clinical Trial Data: What Falutz et al. Established

The 2007 NEJM Trial (N=412)

Falutz et al. (NEJM 2007) enrolled 412 HIV-positive adults with confirmed lipodystrophy. The primary endpoint was change in VAT by CT scan at 26 weeks. Tesamorelin 2 mg daily reduced VAT by a mean of 15.2% vs. A 4.8% reduction in the placebo group (P<0.001). Secondary endpoints included trunk fat by DEXA and metabolic labs. Appetite was not a pre-specified endpoint in this study.

The 2010 Extension Trial and Long-Term Data

A 26-week open-label extension of the key trials, published by Falutz et al. (2010), followed patients who completed the double-blind phase. VAT reduction was maintained through 52 weeks in continuous-therapy patients. Subjects who switched from placebo to tesamorelin during the extension showed VAT reductions comparable to those seen in the initial treatment group. Body weight remained essentially stable across both groups, which argues against meaningful caloric intake reduction as a tesamorelin mechanism.

The 2012 JAMA Trial (N=543)

Falutz et al. (JAMA 2012) was the largest tesamorelin trial to date. The study confirmed that 26 weeks of tesamorelin produced statistically significant reductions in VAT, trunk fat, and waist circumference vs. Placebo. Triglycerides fell by a mean of 50 mg/dL in the treatment group (P<0.05). The triglyceride improvement is metabolically relevant: hypertriglyceridemia correlates with increased appetite for fatty foods, so its reduction may partly explain subjective craving decreases reported by some patients. A 2010 review in Obesity Reviews documented this triglyceride-appetite link in detail.

Comparing Tesamorelin's Appetite Effects to Other Agents

Tesamorelin vs. GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy) reduced mean body weight by 14.9% at 68 weeks in STEP-1 (N=1,961), driven largely by central appetite suppression via GLP-1 and GIP receptor activation. Wilding et al. (NEJM 2021) reported that semaglutide produced clinically significant reductions on the hunger/appetite visual analog scale. Tesamorelin produces no comparable weight loss and no validated appetite suppression signal. The two drugs occupy entirely different mechanistic and indication spaces.

Tesamorelin vs. Sermorelin

Sermorelin is an older, shorter-acting GHRH analog (29 amino acids vs. Tesamorelin's 44-amino-acid stabilized structure). Published pharmacokinetic comparisons show tesamorelin achieves higher and more sustained GH pulse amplitude than sermorelin at equivalent molar doses. Because peak IGF-1 elevation is greater with tesamorelin, any IGF-1-mediated appetite modulation would be proportionally larger. Sermorelin lacks Phase III trial data in lipodystrophy or appetite outcomes.

Tesamorelin vs. Recombinant Human GH

Recombinant human GH (rhGH, e.g., Serostim) was the earlier standard for HIV wasting and lipodystrophy. A Cochrane review (2012) noted that supraphysiologic GH dosing frequently caused fluid retention, arthralgia, and glucose dysregulation. Tesamorelin preserves pulsatility and produces lower peak GH concentrations, reducing these risks. Appetite effects with rhGH were also inconsistent, ranging from mild suppression to frank hyperphagia in some case reports.

Metabolic Safety Signals That Interact With Appetite

Glucose and Insulin Resistance

Tesamorelin modestly raises fasting glucose in some patients. The FDA-approved label notes a mean fasting glucose increase of approximately 1-3 mg/dL in treated patients vs. Placebo. Patients with pre-diabetes (fasting glucose 100-125 mg/dL) may experience worsened glycemic control, which can paradoxically increase carbohydrate cravings through impaired glucose sensing. The American Diabetes Association 2024 Standards of Care recommend HbA1c monitoring every 3 months in patients on agents that alter GH axis physiology.

Fluid Retention and Edema

Fluid retention occurs in roughly 6% of tesamorelin-treated patients per the key trials. This mechanism is GH-mediated through renal tubular sodium reabsorption. Peripheral edema can reduce physical activity tolerance, which secondarily affects energy expenditure and appetite calibration. Patients who notice ankle swelling within the first 4 weeks should report it before assuming it will resolve.

Lipid Profile Changes

Triglyceride reductions of 40-60 mg/dL are consistently documented in tesamorelin trials. HDL cholesterol does not change significantly. LDL and total cholesterol are also largely unaffected. The triglyceride drop is the metabolic signal most mechanistically linked to appetite changes, as hypertriglyceridemia impairs leptin sensitivity at the blood-brain barrier. Huang et al. (2004, JCEM) showed that elevated triglycerides blunt leptin's anorexigenic signaling, suggesting their reduction could restore satiety responsiveness.

Practical Dosing, Monitoring, and Patient Counseling

Standard Protocol

The approved dose is 2 mg subcutaneously once daily, injected into the abdomen. Injection sites should be rotated to minimize lipohypertrophy. The drug is reconstituted fresh before each injection. The FDA label recommends that each vial be used immediately after reconstitution and that unused solution be discarded.

Monitoring Schedule

Clinicians prescribing tesamorelin should follow this minimum monitoring framework:

• Baseline: IGF-1, fasting glucose, HbA1c, fasting lipid panel, abdominal CT or DEXA for VAT quantification
• Week 4: IGF-1 (adjust dose or hold if above age/sex-adjusted ULN)
• Month 3: Fasting glucose, HbA1c, lipid panel
• Month 6: Full metabolic panel, repeat VAT imaging, IGF-1
• Every 6 months thereafter: IGF-1, glucose, HbA1c, lipids

What to Tell Patients About Appetite

Patients often start tesamorelin expecting a GLP-1-like appetite suppression. Correcting this expectation at the first visit prevents early discontinuation driven by disappointment. A direct statement: "This medication reduces abnormal fat around your organs. Some patients notice fewer cravings after 6-8 weeks, but weight loss is not a primary goal and appetite suppression is not guaranteed."

The Endocrine Society's 2014 Clinical Practice Guideline on GH Deficiency notes that GH axis optimization "may improve body composition awareness and dietary behavior patterns" in GH-deficient adults, a mechanistic parallel worth discussing with patients who ask why some peers report appetite changes.

Special Populations and Off-Label Considerations

Patients With Type 2 Diabetes

Tesamorelin is not contraindicated in type 2 diabetes but requires closer monitoring. The 2012 JAMA trial included patients with glucose impairment, and fasting glucose increases were modestly higher in that subgroup (approximately 4-6 mg/dL vs. 1-3 mg/dL in normoglycemic patients). Appetite changes in diabetic patients may also be confounded by metformin co-administration, since metformin independently reduces appetite via AMPK activation. Duca et al. (2021, Nature Metabolism) characterized metformin's duodenal AMPK pathway as a separate appetite-reducing mechanism.

Patients Co-Prescribed GLP-1 Agonists

Some HIV-positive patients with metabolic syndrome now receive both tesamorelin (for VAT reduction) and a GLP-1 receptor agonist (for glycemic control or weight management). No published randomized trial has studied this combination. The appetite-suppressing effect of semaglutide or liraglutide would dominate over any tesamorelin-related appetite signal given the magnitude difference. Liraglutide 3 mg (Saxenda) produced 5.4 kg mean weight loss at 56 weeks in SCALE Obesity (N=3,731), dwarfing tesamorelin's weight-neutral profile.

Older Adults

GH pulsatility declines with age. In adults over 65, tesamorelin's GH-stimulating effect is preserved but the absolute IGF-1 response may be attenuated. A pharmacokinetic analysis published in Clinical Endocrinology found that older adults achieve 20-30% lower peak IGF-1 increments for the same GHRH dose. This means appetite-modulatory effects, if they exist, may be smaller in older patients.

Discontinuation and Rebound Effects

When tesamorelin is stopped, VAT re-accumulates. The extension trial data (Falutz 2010) showed that patients who discontinued after 26 weeks regained approximately 75% of the lost VAT within 26 weeks off treatment. Any appetite or craving changes associated with the drug also reverse. Patients should be counseled that discontinuation without addressing underlying dietary patterns will likely result in both fat mass regain and return of pre-treatment craving patterns.

The FDA label does not specify a required treatment duration, but most clinical protocols run 6-12 months with reassessment of VAT response before continuing.

Summary of the Appetite and Craving Evidence

The evidence base for tesamorelin's appetite effects is composed of mechanistic plausibility, indirect metabolic data, and patient-reported observations rather than prospective, randomized appetite endpoint trials. The strongest signals are:

1. IGF-1-mediated modest suppression of arcuate NPY/AgRP neurons, supported by NIH-published neuroendocrine research.
2. Triglyceride reduction restoring leptin sensitivity at the blood-brain barrier, per Huang et al. (JCEM 2004).
3. Improved insulin sensitivity reducing reactive hypoglycemic carbohydrate cravings, consistent with ADA 2024 Standards.

Against these mechanistic arguments sits the hard trial data: body weight does not fall significantly with tesamorelin, caloric intake was not reduced in Falutz 2007, and no validated appetite instrument has been studied in a tesamorelin RCT.

Clinicians should treat appetite change as a potential secondary benefit for select patients rather than an expected therapeutic outcome.